Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Sep;72(3):615–619. doi: 10.1038/bjc.1995.382

Enhancement of drug sensitivity of human malignancies by epidermal growth factor.

R Kröning 1, J A Jones 1, D K Hom 1, C C Chuang 1, R Sanga 1, G Los 1, S B Howell 1, R D Christen 1
PMCID: PMC2033868  PMID: 7669570

Abstract

We have previously shown that epidermal growth factor (EGF) enhances the in vitro and in vivo sensitivity of human ovarian carcinoma 2008 cells to cisplatin. EGF was found to enhance selectively the in vivo toxicity of cisplatin to 2008 cell xenografts without altering the toxicity of cisplatin to non-malignant target tissues such as the kidney or bone marrow. We now show that recombinant human EGF (rhEGF) enhances the cisplatin sensitivity of cell lines representative of many other types of malignancies in addition to ovarian carcinoma, including cancers of the head and neck, cervix, colon, pancreas and prostate, as well as non-small-cell carcinoma of the lung. In addition, rhEGF was found to sensitise cells to other platinum-containing drugs and several other classes of chemotherapeutic agents. rhEGF sensitised 2008 cells not only to cisplatin, but also to carboplatin and tetraplatin, as well as taxol, melphalan and 5-fluorouracil. We conclude that modulation of drug sensitivity by rhEGF is observed in cell lines representative of many human malignancies and for multiple classes of chemotherapeutic agents, indicating that it alters one or more components of the cellular damage response that are both common between cell lines and classes of drugs and fundamental to survival.

Full text

PDF
616

Images in this article

617Figure 2
on p.617

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiyama S., Fojo A., Hanover J. A., Pastan I., Gottesman M. M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet. 1985 Mar;11(2):117–126. doi: 10.1007/BF01534700. [DOI] [PubMed] [Google Scholar]
  2. Amagase H., Kakimoto M., Hashimoto K., Fuwa T., Tsukagoshi S. Epidermal growth factor receptor-mediated selective cytotoxicity of antitumor agents toward human xenografts and murine syngeneic solid tumors. Jpn J Cancer Res. 1989 Jul;80(7):670–678. doi: 10.1111/j.1349-7006.1989.tb01695.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Banks-Schlegel S. P., Gazdar A. F., Harris C. C. Intermediate filament and cross-linked envelope expression in human lung tumor cell lines. Cancer Res. 1985 Mar;45(3):1187–1197. [PubMed] [Google Scholar]
  4. Christen R. D., Hom D. K., Porter D. C., Andrews P. A., MacLeod C. L., Hafstrom L., Howell S. B. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest. 1990 Nov;86(5):1632–1640. doi: 10.1172/JCI114885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cohen S., Carpenter G. Human epidermal growth factor: isolation and chemical and biological properties. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1317–1321. doi: 10.1073/pnas.72.4.1317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Connolly J. M., Rose D. P. Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line. Prostate. 1989;15(2):177–186. doi: 10.1002/pros.2990150211. [DOI] [PubMed] [Google Scholar]
  7. Devary Y., Gottlieb R. A., Smeal T., Karin M. The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. Cell. 1992 Dec 24;71(7):1081–1091. doi: 10.1016/s0092-8674(05)80058-3. [DOI] [PubMed] [Google Scholar]
  8. DiSaia P. J., Sinkovics J. G., Rutledge F. N., Smith J. P. Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors. Am J Obstet Gynecol. 1972 Dec 1;114(7):979–989. doi: 10.1016/0002-9378(72)90109-3. [DOI] [PubMed] [Google Scholar]
  9. Dive C., Hickman J. A. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer. 1991 Jul;64(1):192–196. doi: 10.1038/bjc.1991.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fogh J., Wright W. C., Loveless J. D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst. 1977 Feb;58(2):209–214. doi: 10.1093/jnci/58.2.209. [DOI] [PubMed] [Google Scholar]
  11. Friedl F., Kimura I., Osato T., Ito Y. Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc Soc Exp Biol Med. 1970 Nov;135(2):543–545. doi: 10.3181/00379727-135-35091a. [DOI] [PubMed] [Google Scholar]
  12. Giard D. J., Aaronson S. A., Todaro G. J., Arnstein P., Kersey J. H., Dosik H., Parks W. P. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973 Nov;51(5):1417–1423. doi: 10.1093/jnci/51.5.1417. [DOI] [PubMed] [Google Scholar]
  13. Graziano S. L., Pfeifer A. M., Testa J. R., Mark G. E., Johnson B. E., Hallinan E. J., Pettengill O. S., Sorenson G. D., Tatum A. H., Brauch H. Involvement of the RAF1 locus, at band 3p25, in the 3p deletion of small-cell lung cancer. Genes Chromosomes Cancer. 1991 Jul;3(4):283–293. doi: 10.1002/gcc.2870030407. [DOI] [PubMed] [Google Scholar]
  14. Haley J. D. Regulation of epidermal growth factor receptor expression and activation: a brief review. Symp Soc Exp Biol. 1990;44:21–37. [PubMed] [Google Scholar]
  15. Holbrook N. J., Fornace A. J., Jr Response to adversity: molecular control of gene activation following genotoxic stress. New Biol. 1991 Sep;3(9):825–833. [PubMed] [Google Scholar]
  16. Howell S. B., Zimm S., Markman M., Abramson I. S., Cleary S., Lucas W. E., Weiss R. J. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol. 1987 Oct;5(10):1607–1612. doi: 10.1200/JCO.1987.5.10.1607. [DOI] [PubMed] [Google Scholar]
  17. Isonishi S., Andrews P. A., Howell S. B. Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem. 1990 Mar 5;265(7):3623–3627. [PubMed] [Google Scholar]
  18. Isonishi S., Jekunen A. P., Hom D. K., Eastman A., Edelstein P. S., Thiebaut F. B., Christen R. D., Howell S. B. Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha. J Clin Invest. 1992 Oct;90(4):1436–1442. doi: 10.1172/JCI116010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kaye S. B., Lewis C. R., Paul J., Duncan I. D., Gordon H. K., Kitchener H. C., Cruickshank D. J., Atkinson R. J., Soukop M., Rankin E. M. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 1992 Aug 8;340(8815):329–333. doi: 10.1016/0140-6736(92)91404-v. [DOI] [PubMed] [Google Scholar]
  20. Krause C. J., Carey T. E., Ott R. W., Hurbis C., McClatchey K. D., Regezi J. A. Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch Otolaryngol. 1981 Nov;107(11):703–710. doi: 10.1001/archotol.1981.00790470051012. [DOI] [PubMed] [Google Scholar]
  21. Kwok T. T., Sutherland R. M. Enhancement of sensitivity of human squamous carcinoma cells to radiation by epidermal growth factor. J Natl Cancer Inst. 1989 Jul 5;81(13):1020–1024. doi: 10.1093/jnci/81.13.1020. [DOI] [PubMed] [Google Scholar]
  22. Lieber M., Smith B., Szakal A., Nelson-Rees W., Todaro G. A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer. 1976 Jan 15;17(1):62–70. doi: 10.1002/ijc.2910170110. [DOI] [PubMed] [Google Scholar]
  23. Mann S. C., Andrews P. A., Howell S. B. Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer. 1991 Jul 30;48(6):866–872. doi: 10.1002/ijc.2910480613. [DOI] [PubMed] [Google Scholar]
  24. Mickey D. D., Stone K. R., Wunderli H., Mickey G. H., Vollmer R. T., Paulson D. F. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res. 1977 Nov;37(11):4049–4058. [PubMed] [Google Scholar]
  25. Saggi S. J., Safirstein R., Price P. M. Cloning and sequencing of the rat preproepidermal growth factor cDNA: comparison with mouse and human sequences. DNA Cell Biol. 1992 Jul-Aug;11(6):481–487. doi: 10.1089/dna.1992.11.481. [DOI] [PubMed] [Google Scholar]
  26. Schaefer F., Seidel C., Binding A., Gasser T., Largo R. H., Prader A., Schärer K. Pubertal growth in chronic renal failure. Pediatr Res. 1990 Jul;28(1):5–10. doi: 10.1203/00006450-199007000-00002. [DOI] [PubMed] [Google Scholar]
  27. Semple T. U., Quinn L. A., Woods L. K., Moore G. E. Tumor and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxicity model. Cancer Res. 1978 May;38(5):1345–1355. [PubMed] [Google Scholar]
  28. Taetle R., Jones O. W., Honeysett J. M., Abramson I., Bradshaw C., Reid S. Use of nude mouse xenografts as preclinical screens. Characterization of xenograft-derived melanoma cell lines. Cancer. 1987 Oct 15;60(8):1836–1841. doi: 10.1002/1097-0142(19871015)60:8<1836::aid-cncr2820600827>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  29. Wilson A. P., Ford C. H., Newman C. E., Howell A. cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment. Br J Cancer. 1987 Dec;56(6):763–773. doi: 10.1038/bjc.1987.285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wolf C. R., Hayward I. P., Lawrie S. S., Buckton K., McIntyre M. A., Adams D. J., Lewis A. D., Scott A. R., Smyth J. F. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer. 1987 Jun 15;39(6):695–702. doi: 10.1002/ijc.2910390607. [DOI] [PubMed] [Google Scholar]
  31. Yunis A. A., Arimura G. K., Russin D. J. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer. 1977 Jan;19(1):128–135. doi: 10.1002/ijc.2910190118. [DOI] [PubMed] [Google Scholar]
  32. Zijlstra J. G., de Vries E. G., Mulder N. H. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 1987 Apr 1;47(7):1780–1784. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES